Vivos Therapeutics, Inc.
VVOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $34 | $29 | $24 | $25 |
| - Cash | $3 | $4 | $2 | $6 |
| + Debt | $4 | $12 | $1 | $2 |
| Enterprise Value | $35 | $36 | $24 | $21 |
| Revenue | $7 | $4 | $3 | $4 |
| % Growth | 77.6% | 26.7% | -18.4% | – |
| Gross Profit | $4 | $2 | $2 | $2 |
| % Margin | 58% | 55.2% | 50% | 56.7% |
| EBITDA | -$5 | -$5 | -$4 | -$3 |
| % Margin | -73.9% | -123.2% | -118.2% | -72.6% |
| Net Income | -$5 | -$5 | -$4 | -$3 |
| % Margin | -79.6% | -131.2% | -128.1% | -76.4% |
| EPS Diluted | -0.49 | -0.55 | -0.45 | -0.48 |
| % Growth | 10.9% | -22.2% | 6.2% | – |
| Operating Cash Flow | -$4 | -$3 | -$4 | -$3 |
| Capital Expenditures | $1 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$3 | -$4 | -$4 | -$3 |